These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161 [TBL] [Abstract][Full Text] [Related]
5. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210 [TBL] [Abstract][Full Text] [Related]
6. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
8. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735 [TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487 [TBL] [Abstract][Full Text] [Related]
10. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987 [TBL] [Abstract][Full Text] [Related]
11. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866 [TBL] [Abstract][Full Text] [Related]
12. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. Chen YM J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257 [TBL] [Abstract][Full Text] [Related]
13. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related]
14. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746 [TBL] [Abstract][Full Text] [Related]
15. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib. Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510 [TBL] [Abstract][Full Text] [Related]
16. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430 [TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms. Jiang Y; Yuan Q; Fang Q J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway. Li N; Zuo R; He Y; Gong W; Wang Y; Chen L; Luo Y; Zhang C; Liu Z; Chen P; Guo H Cell Death Dis; 2024 Aug; 15(8):555. PubMed ID: 39090096 [TBL] [Abstract][Full Text] [Related]
19. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Murphy M; Stordal B Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]